Key facts
- This page summarizes Mason Freeman's Form 4 filing for CinCor Pharma, Inc..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 13 Jan 2022, 15:28.
Mason Freeman - 11 Jan 2022 Form 4 Insider Report for CinCor Pharma, Inc.
- Reporting relationship
- EVP Clinical Development
- Issuer ticker
- N/A
- Reported as of
- 11 Jan 2022
- Net transaction value
- +$41,600
- SEC form
- 4
- Accepted by SEC
- 13 Jan 2022, 15:28:20 UTC
- Prior SEC filing
- 06 Jan 2022
- Next SEC filing
- 27 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Cathy Rude, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mason Freeman filed Form 4 for CinCor Pharma, Inc. on 13 Jan 2022.
Change
- Previous filing in this sequence was filed on 06 Jan 2022.
- Current net transaction value: +$41,600.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CINC
transaction
Common Stock
Purchase
- Transaction value
- $40,000
- Shares
- +2,500
- Change %
- Price
- $16.00
- Shares after
- 2,500
- Date
- 11 Jan 2022
- Ownership
- Direct
CINC
transaction
Common Stock
Purchase
- Transaction value
- $1,600
- Shares
- +100
- Change %
- Price
- $16.00
- Shares after
- 100
- Date
- 11 Jan 2022
- Ownership
- By spouse
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The securities are held by the Reporting Person's spouse. The Reporting Person shares voting and investment control of the shares and may be deemed to beneficially own the shares. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his proportionate pecuniary interest therein.